Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab
Open Access
- 21 February 2025
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-11
Abstract
Kidney transplant recipients (KTRs) have an elevated fracture risk. While dual-energy X-ray absorptiometry (DXA) is commonly used to assess areal bone mineral density (aBMD), it does not capture all aspects of bone quality. We investigated the long-term effects on bone DXA-derived indices of bone quality in KTRs treated with denosumab and untreated with denosumab. This is a retrospective study, including KTRs treated with denosumab and untreated age and sex-matched KTR controls. DXA-derived parameters, including trabecular bone score (TBS) and 3D-DXA parameters, were measured at the lumbar spine and femur at baseline and after four years. Hierarchical linear models were used to assess the between-group effect of treatment over time, also adjusting for site-specific aBMDs. We enrolled 23 KTRs treated with denosumab and 23 KTR denosumab-untreated KTRs. Significant between-group differences over time in favor of the denosumab group were observed for TBS (0.843, 95%CI 0.439; 1.248, p < 0.001), trabecular volumetric BMD at the total hip (Tb.vBMD TH) (13.492, 95%CI 1.707; 25.278, p = 0.003), cortical volumetric BMD at the femoral neck (Ct.vBMD FN) (28.766, 95%CI 8.373; 49.158, p = 0.008), cortical surface BMD at the total hip (c.sBMD TH) (10.507, 95%CI 4.140; 16.873, p = 0.002), cortical surface at the femoral neck (c.sBMD FN) (8.795, 95%CI 2.818; 14.771, p = 0.006), and cortical thickness at the total hip (Ct.th.TH) (0.075, 95%CI 0.020; 0.130, p = 0.010). After adjusting for BMD, the differences on TBS and Ct.vBMD FN and c.sBMD FN remained significant. Denosumab treatment in KTRs was associated with better outcomes in terms of bone quality and geometry parameters, independent of changes in aBMD.Keywords
Funding Information
- Università degli Studi di Verona
This publication has 47 references indexed in Scilit:
- Prevalence of low bone mineral density (T-score ≤ − 2.5) in the whole spectrum of chronic kidney disease: a systematic review and meta-analysisOsteoporosis International, 2022
- Frequency of normal bone measurement in postmenopausal women with fracture: a registry-based cohort studyOsteoporosis International, 2020
- Trabecular bone score in patients with chronic kidney diseaseOsteoporosis International, 2020
- Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modelingOsteoporosis International, 2018
- The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney diseaseOsteoporosis International, 2018
- Low bone mineral density and fractures in stages 3–5 CKD: an updated systematic review and meta-analysisOsteoporosis International, 2014
- Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With OsteoporosisJournal of Bone and Mineral Research, 2014
- Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronateJournal of Bone and Mineral Research, 2010
- Bone strength and its determinantsOsteoporosis International, 2003
- Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal WomenJAMA, 2001